Product
Donor CD34+, CD3+ and Belumosudil
1 clinical trial
4 indications
Indication
End-Stage Renal DiseaseIndication
Immunological ToleranceIndication
Kidney Transplant Failure and RejectionIndication
Chronic Kidney DiseaseClinical trial
Use of the Immunomodulating Agent Belumosudil (KD025) After Combined Kidney and Hematopoeitic Stem Cell Transplantation to Induce Transplant Tolerance: A Pilot StudyStatus: Active (not recruiting), Estimated PCD: 2025-08-01